Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Roche’s Elevidys Receives Negative CHMP Opinion for Duchenne Muscular Dystrophy

Fineline Cube Jul 28, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced today that the Committee for Medicinal...

Company Drug

Aidea Pharma’s Aitribond Approved by Zanzibar Food and Drug Agency

Fineline Cube Jul 28, 2025

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that its anti-HIV-1 drug Aitribond has...

Company Deals

Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan

Fineline Cube Jul 28, 2025

Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into...

Company Drug

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Fineline Cube Jul 28, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first participants with obesity or overweight...

Company Drug

Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment

Fineline Cube Jul 28, 2025

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), announced today...

Company Deals

Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821

Fineline Cube Jul 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it...

Company Drug

Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod

Fineline Cube Jul 28, 2025

US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...

Company Medical Device

Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification

Fineline Cube Jul 28, 2025

China-based Sansure Biotech Inc. (SHA: 688289) announced on July 28, 2025, that it has received...

Policy / Regulatory

NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale

Fineline Cube Jul 28, 2025

China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...

Company Drug

Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment

Fineline Cube Jul 28, 2025

US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Others

GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 28, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jul 28, 2025

France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...

Company Deals

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials

Fineline Cube Jul 28, 2025

Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...

Company Deals

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases

Fineline Cube Jul 28, 2025

Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...

Company Drug

SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials

Fineline Cube Jul 25, 2025

China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...

Company Drug

Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval

Fineline Cube Jul 25, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...

Company Medical Device

Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation

Fineline Cube Jul 25, 2025

China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...

Company Deals

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707

Fineline Cube Jul 25, 2025

China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...

Company

Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion

Fineline Cube Jul 25, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...

Company Drug

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer

Fineline Cube Jul 25, 2025

China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...

Posts pagination

1 … 176 177 178 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.